Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Codeine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 9/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 5/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.76 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.76 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Codeine SCHEMBL10329428 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL16922140 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL8218174 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL13696342 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL3257 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL1560699 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL12638890 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL14371354 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL21077535 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL16922135 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220362160-A1 | ABUSE RESISTANT CAPSULE | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-11-17 | — | — | US | claimed |
| EP-3446681-B1 | ABUSE RESISTANT CAPSULE | SCHERER TECHNOLOGIES LLC R P (US) | 2020-12-23 | — | — | EP | claimed |
| US-10420729-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2019-09-24 | — | — | US | claimed |
| EP-2968129-B1 | ABUSE RESISTANT CAPSULE | SCHERER TECHNOLOGIES LLC R P (US) | 2018-09-05 | — | — | EP | claimed |
| US-20140271835-A1 | ABUSE RESISTANT CAPSULE | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2014-09-18 | — | — | US | claimed |
| EP-2137189-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | Mallinckrodt Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| EP-1562953-B1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC (US) | 2009-09-30 | — | — | EP | claimed |
| WO-2008109156-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC. (US) | 2008-09-12 | — | — | WO | claimed |
| US-7285665-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT INC. (US) | 2007-10-23 | — | — | US | claimed |
| US-20060014771-A1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | SpecGx LLC | 2006-01-19 | — | — | US | claimed |
| EP-1562953-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | Mallinckrodt Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004043964-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC. (US) | 2004-05-27 | — | — | WO | claimed |
| US-20230390210-A1 | MODIFIED RELEASE SOFTGEL CAPSULES | R.P. SCHERER TECHNOLOGIES, LLC | 2023-12-07 | — | — | US | disclosed |
| US-20230372252-A1 | CONTROLLED RELEASE FILL COMPOSITIONS AND CAPSULES CONTAINING SAME | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2023-11-23 | — | — | US | disclosed |
| US-11571390-B2 | Abuse deterrent compositions and methods of use | Othemo Life Sciences, Inc. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220362160-A1 | ABUSE RESISTANT CAPSULE | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-11-17 | — | — | US | disclosed |
| EP-0274845-B1 | STABLE SOLID PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN AND CODEINE | The Boots Company PLC (GB) | 1990-09-26 | — | — | EP | disclosed |
| US-4839176-A | IBUPROFEN, CODIENE OR THEIR SALTS, CARBOXYMETHYLCELLULOSE INSOLUBLE SALT | BOOTS COMPANY PLC (GB) | 1989-06-13 | — | — | US | disclosed |
| EP-0274845-A1 | Stable solid pharmaceutical composition containing ibuprofen and codeine | The Boots Company PLC (GB) | 1988-07-20 | — | — | EP | disclosed |
| EP-0159852-A2 | Directly compressible pharmaceutical compositions | MALLINCKRODT, INC.(a Missouri corporation) (US) | 1985-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014771-A1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | TTN, PML, EMD | OPRD1 164/4885OPRM1 45/4885OPRK1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.